A comparison between CE FL-DNA and RT FL-DNA to evaluate the best valid method to quantify FL-DNA from stool samples in detecting tumor and tumor and high-risk adenoma patients
| CE FL-DNA | RT FL-DNA | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cutoffs (ng) | CRC | Othersa | % Sensitivity (95% CI) | % Specificity (95% CI) | % Accuracy (95% CI) | CRC | Othersa | % Sensitivity (95% CI) | % Specificity (95% CI) | % Accuracy (95% CI) |
| Positive | Positive | |||||||||
| ≥10 | 21 | 123 | 91(73–97) | 44 (37–50) | 48 (42–54) | 17 | 44 | 74 (53–87) | 80 (74–85) | 79 (74–84) |
| ≥15 | 18 | 71 | 78 (58–90) | 67 (61–73) | 68 (62–74) | 16 | 29 | 70 (49–84) | 87 (82–91) | 85 (80–89) |
| ≥20 | 16 | 46 | 70 (49–84) | 79 (73–84) | 78 (72–83) | 14 | 19 | 61 (41–78) | 91 (87–85) | 88 (84–92) |
| ≥25 | 13 | 34 | 57 (37–74) | 84 (79–89) | 82 (76–86) | 13 | 12 | 57 (37–74) | 94 (91–97) | 91 (87–94) |
| ≥30 | 12 | 21 | 52 (33–71) | 90 (86–94) | 87 (82–90) | 13 | 5 | 57 (37–74) | 98 (95–99) | 94 (90–96) |
| CRC + HRA | Othersb | CRC + HRA | Othersb | |||||||
| Positive | Positive | |||||||||
| ≥10 | 40 | 104 | 71 (58–82) | 44 (37–51) | 50 (44–55) | 23 | 38 | 41 (29–54) | 79 (73–85) | 71 (65–76) |
| ≥15 | 27 | 62 | 48 (36–61) | 66 (59–73) | 62 (56–68) | 22 | 23 | 39 (28–52) | 88 (82–92) | 76 (71–81) |
| ≥20 | 23 | 39 | 41 (29–54) | 79 (72–84) | 70 (64–76) | 17 | 16 | 30 (20–43) | 91 (86–95) | 77 (72–82) |
| ≥25 | 18 | 29 | 32 (21–45) | 84 (78–89) | 72 (66–77) | 15 | 10 | 27 (17–40) | 95 (90–97) | 79 (74–84) |
| ≥30 | 15 | 18 | 27 (17–40) | 90 (85–94) | 76 (70–81) | 15 | 3 | 27 (17–40) | 98 (95–99) | 82 (76–86) |
NOTE: Sensitivity, true-positive rates; specificity, true-negative rates; accuracy, number of true positive plus number of true negative, divided by the total series.
Abbreviations: CRC, colorectal cancer patients; HRA, high-risk adenoma patients.